CG Pharmaceuticals Announces the Commencement of Phase 2 Study for Metastatic Pancreatic Cancer

ORINDA, Calif., Nov. 17, 2023. CG Pharmaceuticals announces the commencement of Phase 2 study for metastatic pancreatic ductal adenocarcinoma (PDAC) with the recommended Phase 2 dose (RP2D) of ivaltinostat (ClinicalTrials.gov ID NCT05249101). The...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials